Atlas Venture intends to sell $8.37M in Dyne stock, continuing recent distribution
DYN has more than doubled off its 52-week low of $11.645.
Summary
Atlas Venture Opportunity Fund I, LP, an institutional shareholder, filed a Form 144 indicating its intent to sell $8.37 million worth of Dyne Therapeutics common stock, adding to recent sales by affiliated funds.
Key Events · Ownership and Investor Activity · DYN
-
Proposed Stock Sale
Atlas Venture Opportunity Fund I, LP filed a Form 144 to sell 322,465 shares of common stock, valued at approximately $8.37 million.
-
Ongoing Institutional Distribution
This proposed sale is part of a broader pattern of distribution by Atlas Venture entities, which have sold over $30 million in Dyne stock in the past three months, as detailed in the supplementary exhibits.
-
Filer Identity
The seller is Atlas Venture Opportunity Fund I, LP, an institutional shareholder.
Analysis · DYN · Life Sciences
This Form 144 indicates that Atlas Venture Opportunity Fund I, LP plans to sell a significant block of Dyne Therapeutics shares. This follows a pattern of distribution by Atlas Venture entities, which have sold over $30 million in Dyne stock in the past three months, as shown in the supplementary exhibits. While not an immediate sale, this intent to sell by a major institutional holder, especially with the stock trading near 52-week highs, suggests a continued rebalancing or reduction of their position, which could create an overhang on the stock.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 28.9% of the 1476 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYN was trading at $25.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $11.65 to $27.31. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.